Stock Surge Is a Bear-Market Trap With Curve Inverted, BofA Warns



Is Novavax Stock a Buy Right Now? This Is What You Need to Know

Novavax (NVAX) might still be waiting for emergency use authorization (EUA) in the US for its Covid-19 vaccine NVX-CoV2373, but B. Riley analyst Mayank Mamtani notes two recent key developments which bolster the vaccine’s “long-term competitive positioning.” One concerns a recent head-to-head immune profiling study overseen by “independent, highly reputable research groups (La Jolla Institute, USCD)” which showed that, both on durability and cross-variant protection, Novavax’ offering was “at le

S&P 500 exits correction: Here’s what history says happens next to U.S. stock-market benchmark

Previous article

What Percent of Your Salary Should Go Toward Retirement

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News